The additional $50 million will go towards venture capital firms that specialize in near- and long-term healthcare solutions for patients in low- and middle-income countries
Acquisition of XinThera provides Gilead with precision small molecules focused on PARP1 and MK2 Inhibitors
Both the companies intend to facilitate faster clinical trial enrollment and provide patients with access to novel medications
Nous-209 has been developed using the Nouscom's viral vector platform
The YP-P10 pre-clinical head-to-head study, jointly conducted by five people including Dr. Kyungho Park of Naason Science
CEQUA is the first dry eye treatment available in India that is delivered with nanomicellar (NCELL) technology
This is the first time the Agency has authorized the Phase 3 clinical evaluation in the U.S of a microbiota-based live biotherapeutic based on a pooling technology
The acquisition is a crucial step in LTS' strategy to broaden its portfolio of drug delivery platforms.
Franson will help biopharma clients design a phased approach to inform and execute clinical development plans
Study efficacy measures will include the expression of dystrophin protein and motor function.
Subscribe To Our Newsletter & Stay Updated
